Labcorp is working hard, combining the power of new high precision technology with artificial intelligence to advance diagnostic testing in order to provide clear, objective answers to clinicians, patients, and families.

We are working with blood-based biomarkers, like pTau and NfL, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.


  1. Alzheimer’s Association.
  2. Anderson LA, Day KL, Beard RL, “The Public's Perceptions About Cognitive Health and Alzheimer's Disease Among the U.S. Population: A National Review”. The Gerontologist. 2009; 49(S1): S3–S11.
  3. 1. Palmqvist S, Zetterberg H, Mattsson N, “Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.” Neurology. 2015;85:1–10
  4. 2. Hansson O, Seibyl J, Stomrud E, “CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.” Alzheimer’s & Dementia. 2018; 14(11): P1470-1481.

 Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Multiple Sclerosis

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.

Biomarkers for Drug Development

The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.